1-9 of 9
Frederick Locke, MD
Close
Sort by
Articles

Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor

Tony J. Kurian, MD, Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2021) 18 (6)
https://doi.org/10.1182/hem.V18.6.202168
Published: 2021
Articles

Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy

Dasom Lee, MD, Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2021) 18 (5)
https://doi.org/10.1182/hem.V18.5.202154
Published: 2021
Articles

IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity

Ariel Perez-Perez, MD, Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2021) 18 (4)
https://doi.org/10.1182/hem.V18.4.202147
Published: 2021
Articles

Predicting and Managing Toxicities of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma

Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2020) 18 (1)
Published: 2020
Articles

CAR T-cell Therapy Hopes to Move to Second Line in Diffuse Large B-cell Lymphoma

Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2020) 17 (6)
Published: 2020
Articles

The L-MIND Trial of the Anti-CD19 Antibody Tafasitamab Combined With Lenalidomide for Lower Risk Relapsed DLBCL

Michael Jain, MD, PhD, Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2020) 17 (5)
Published: 2020
Articles

Ruxolitinib: A Long-Awaited Standard for Steroid Refractory Acute Graft-Versus-Host Disease

Hany Elmariah, MD, MS, Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2020) 17 (4)
https://doi.org/10.1182/hem.V17.4.12884901915
Published: 2020
Articles

CD19 Chimeric Antigen Receptor Natural Killer Cells Can Safely Induce Remission in Lymphoid Malignancies

Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2020) 17 (3)
https://doi.org/10.1182/hem.V17.3.10367
Published: 2020
Articles

CAR Design, Independent of Costimulatory Domain, Impacts Safety and Immunogenicity of CAR T-cell Therapy

Frederick Locke, MD
Journal: The Hematologist
The Hematologist (2020) 17 (2)
https://doi.org/10.1182/hem.V17.2.10280
Published: 2020